Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

1.

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients.

Endrikat J, Kim SY, Sakaguchi T, Dohanish S, Breuer J.

Acta Radiol. 2015 Jun 4. pii: 0284185115588126. [Epub ahead of print]

PMID:
26048848
2.

0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes.

Gerlinger C, Gude K, Schmelter T, Schaefers M, Endrikat J.

Climacteric. 2015 Aug;18(4):512-7. doi: 10.3109/13697137.2015.1036855. Epub 2015 May 22.

PMID:
26000627
3.
4.

Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.

Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J.

Invest Radiol. 2015 Jun;50(6):416-22. doi: 10.1097/RLI.0000000000000145.

5.

Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.

Endrikat JS, Dohanish S, Balzer T, Breuer JA.

J Magn Reson Imaging. 2015 Feb 2. doi: 10.1002/jmri.24838. [Epub ahead of print]

PMID:
25643844
6.

Misoprostol for pre-term labor induction in the second trimester: Role of medical history and clinical parameters for prediction of time to delivery.

di Liberto A, Endrikat J, Frohn S, Solomayer E, Ertan K.

J Turk Ger Gynecol Assoc. 2014 Aug 8;15(3):130-4. doi: 10.5152/jtgga.2014.13034. eCollection 2014.

7.

Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population.

Gerlinger C, Trussell J, Mellinger U, Merz M, Marr J, Bannemerschult R, Schellschmidt I, Endrikat J.

Contraception. 2014 Aug;90(2):142-6. doi: 10.1016/j.contraception.2014.03.018. Epub 2014 Apr 13.

8.

Axillary ultrasound for breast cancer staging: an attempt to identify clinical/histopathological factors impacting diagnostic performance.

Ertan K, Linsler C, di Liberto A, Ong MF, Solomayer E, Endrikat J.

Breast Cancer (Auckl). 2013;7:35-40. doi: 10.4137/BCBCR.S11215. Epub 2013 Mar 6.

9.

Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study.

Endrikat J, Parke S, Trummer D, Serrani M, Duijkers I, Klipping C.

Contraception. 2013 Feb;87(2):227-34. doi: 10.1016/j.contraception.2012.07.008. Epub 2012 Sep 17.

PMID:
22995539
10.

Estimation of menstrual blood loss volume based on menstrual diary and laboratory data.

Schumacher U, Schumacher J, Mellinger U, Gerlinger C, Wienke A, Endrikat J.

BMC Womens Health. 2012 Aug 20;12:24. doi: 10.1186/1472-6874-12-24.

11.

Postnatal neuro-development of fetuses with absent end-diastolic flow in the umbilical artery and/or fetal descending aorta.

Ertan AK, Tanriverdi HA, Stamm A, Jost W, Endrikat J, Schmidt W.

Arch Gynecol Obstet. 2012 Jun;285(6):1547-52. doi: 10.1007/s00404-011-2191-4. Epub 2012 Jan 4.

PMID:
22215198
12.

Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide.

Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B.

Contraception. 2011 Dec;84(6):549-57. doi: 10.1016/j.contraception.2011.04.009. Epub 2011 Jun 8. Review.

PMID:
22078182
13.

Chromosomal abnormalities in fetuses with ultrasonographically detected neural tube defects.

Kanit H, Özkan AA, Öner SR, Ispahi C, Endrikat JS, Ertan K.

Clin Dysmorphol. 2011 Oct;20(4):190-3. doi: 10.1097/MCD.0b013e328348d99d.

PMID:
21709547
14.

The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia.

Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E.

Arch Gynecol Obstet. 2012 Jan;285(1):117-21. doi: 10.1007/s00404-011-1902-1. Epub 2011 Apr 8.

PMID:
21475963
15.

Pattern recognition in menstrual bleeding diaries by statistical cluster analysis.

Gerlinger C, Wessel J, Kallischnigg G, Endrikat J.

BMC Womens Health. 2009 Jul 16;9:21. doi: 10.1186/1472-6874-9-21.

16.

A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia.

Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M.

J Obstet Gynaecol Can. 2009 Apr;31(4):340-7.

PMID:
19497153
17.

Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada.

Endrikat JS, Milchev NP, Kapamadzija A, Georgievska J, Gerlinger C, Schmidt W, Feroze S.

Contraception. 2009 Jun;79(6):428-32. doi: 10.1016/j.contraception.2008.12.007. Epub 2009 Feb 7.

PMID:
19442777
18.

Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.

Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C.

Contraception. 2008 Sep;78(3):218-25. doi: 10.1016/j.contraception.2008.05.004. Epub 2008 Jul 11.

PMID:
18692612
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk